Renal denervation -implications for chronic kidney disease

Nature Reviews Nephrology

Volumn 10, Issue 6, 2014, Pages 305-313

  Veelken, Roland ^a   Schmieder, Roland E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY DISEASE; EFFERENT NERVE; GLUCOSE METABOLISM; HUMAN; INSULIN SENSITIVITY; KIDNEY DENERVATION; NEPHRITIS; PRIORITY JOURNAL; RENAL PROTECTION; RESISTANT HYPERTENSION; REVIEW; SENSORY NERVE; SYMPATHETIC TONE; AUTONOMIC DENERVATION; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; SURGERY;

AUTONOMIC DENERVATION; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84901692637     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.59     Document Type: Review

References (86)

1. Mailloux, L. U. & Haley, W. E. Hypertension in the ESRD patient: Pathophysiology, therapy, outcomes, and future directions. Am. J. Kidney Dis. 32, 705-719 (1998
2. Ritz, E., Rychlik, I., Locatelli, F. & Halimi, S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 34, 795-808 (1999
3. Klag, M. J. et al. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 334, 13-18 (1996
4. Rostand, S. G., Brunzell, J. D., Cannon, R. O. 3rd & Victor, R. G. Cardiovascular complications in renal failure. J. Am. Soc. Nephrol. 2, 1053-1062 (1991
5. Herzog, C. A., Ma, J. Z. & Collins, A. J. Poor long-Term survival after acute myocardial infarction among patients on long-Term dialysis. N. Engl. J. Med. 339, 799-805 (1998
6. Coresh, J. et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 161, 1207-1216 (2001
7. Tonelli, M. et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am. J. Kidney Dis. 37, 484-489 (2001
8. Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof of principle cohort study. Lancet 373, 1275-1281 (2009
9. Medtronic Inc. Press release: Medtronic announces US renal denervation pivotal trial fails to meet primary efficacy endpoint while meeting primary safety endpoint. Medtronic [online] http://newsroom.medtronic.com/phoenix.zhtml? c=251324&p=irol-newsArticle&ID=1889335&highlight=&utm-source= MDT-com-Symplifybptrial-Home-Page&utm-medium=Impt-Info-ReadPR-Link&utm- campaign=Renal-Denervation-RDN-Press-Release-010914 (2014
10. Campese, V. M. & Kogosov, E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25, 878-882 (1995
11. Campese, V. M., Kogosov, E. & Koss, M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am. J. Kidney Dis. 26, 861-865 (1995
12. Amann, K. et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J. Am. Soc. Nephrol. 11, 1469-1478 (2000
13. Veelken, R. et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J. Am. Soc. Nephrol. 19, 1371-1378 (2008
14. Strojek, K., Grzeszczak, W., Gorska, J., Leschinger, M. I. & Ritz, E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: Novel approach to prevent progression of diabetic nephropathy?. J. Am. Soc. Nephrol. 12, 602-605 (2001
15. Kim, K. E., Onesti, G., Schwartz, A. B., Chinitz, J. L. & Swartz, C. Hemodynamics of hypertension in chronic end-stage renal disease. Circulation 46, 456-464 (1972
16. McGrath, B. P. et al. Autonomic blockade and the Valsalva maneuver in patients on maintenance hemodialysis: A hemodynamic study. Kidney Int. 12, 294-302 (1977
17. Levitan, D., Massry, S. G., Romoff, M. & Campese, V. M. Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: Effect of clonidine. Nephron 36, 24-29 (1984
18. Converse, R. L. Jr et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327, 1912-1918 (1992
19. Hausberg, M. et al. Sympathetic nerve activity in end-stage renal disease. Circulation 106, 1974-1979 (2002
20. Grassi, G. et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 57, 846-851 (2011
21. DiBona, G. F. & Kopp, U. C. Neural control of renal function. Physiol. Rev. 77, 75-197 (1997
22. DiBona, G. F. & Esler, M. Translational medicine: The antihypertensive effect of renal denervation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R245-R253 (2010
23. DiBona, G. F. & Sawin, L. L. Renal nerves in renal adaption to dietary sodium restriction. Am. J. Physiol. 245, F322-F328 (1983
24. Friberg, P. et al. Evidence for increased renal norepinephrine overflow during sodium restriction in humans. Hypertension 16, 121-130 (1990
25. Kopp, U. C., Cicha, M. Z. & Smith, L. A. Dietary sodium loading increases arterial pressure in afferent renal-denervated rats. Hypertension 42, 968-973 (2003
26. Xie, C. & Wang, D. H. Effects of a high-salt diet on TRPV 1 dependent renal nerve activity in Dahl salt-sensitive rats. Am. J. Nephrol. 32, 194-200 (2010
27. Stella, A. & Zanchetti, A. Functional role of renal afferents. Physiol. Rev. 71, 659-682 (1991
28. Kopp, U. C., Farley, D. M., Cicha, M. Z. & Smith, L. A. Activation of renal mechanosensitive neurons involves bradykinin, protein kinase C, PGE2, and substance P. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278, R937-R946 (2000
29. Xie, C., Sachs, J. R. & Wang, D. H. Interdependent regulation of afferent renal nerve activity and renal function: Role of transient receptor potential vanilloid type 1, neurokinin 1, and calcitonin gene-related peptide receptors. J. Pharmacol. Exp. Ther. 325, 751-757 (2008
30. Ditting, T. et al. Tonic postganglionic sympathetic inhibition induced by afferent renal nerves?. Hypertension 59, 467-476 (2012
31. Hering, D. et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 61, 457-464 (2013
32. Wyss, J. M., Aboukarsh, N. & Oparil, S. Sensory denervation of the kidney attenuates renovascular hypertension in the rat. Am. J. Physiol. 250, H82-H86 (1986
33. Ye, S., Zhong, H., Yanamadala, V. & Campese, V. M. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am. J. Hypertens. 15, 717-724 (2002
34. Wyss, J. M., Oparil, S. & Sripairojthikoon, W. Neuronal control of the kidney: Contribution to hypertension. Can. J. Physiol. Pharmacol. 70, 759-770 (1992
35. Brinkmann, J. et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult to control hypertensive patients: Prospective case series. Hypertension 60, 1485-1490 (2012
36. Macefield, V. G., Wallin, B. G. & Vallbo, A. B. The discharge behaviour of single vasoconstrictor motoneurones in human muscle nerves. J. Physiol. 481 (Pt 3), 799-809 (1994
37. Greenwood, J. P., Stoker, J. B. & Mary, D. A. Single-unit sympathetic discharge: Quantitative assessment in human hypertensive disease. Circulation 100, 1305-1310 (1999
38. Schlaich, M. P. et al. Effects of transcatheter renal nerve ablation on sympathetic and neurohormonal activity in patients with resistant hypertension [abstract]. J. Hypertens. 30 (e-Suppl. 1), a787 (2012
39. Oliveras, A. et al. Urinary albumin excretion is associated with true resistant hypertension. J. Hum. Hypertens. 24, 27-33 (2010
40. Amann, K. et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J. Am. Soc. Nephrol. 11, 1469-1478 (2000
41. Wolf, G., Helmchen, U. & Stahl, R. A. Isoproterenol stimulates tubular DNA replication in mice. Nephrol. Dial. Transplant. 11, 2288-2292 (1996
42. Pavenstadt, H. Roles of the podocyte in glomerular function. Am. J. Physiol. Renal. Physiol. 278, F173-F179 (2000
43. Reinecke, M. & Forssmann, W. G. Neuropeptide (neuropeptide Y, neurotensin, vasoactive intestinal polypeptide, substance P, calcitonin gene-related peptide, somatostatin) immunohistochemistry and ultrastructure of renal nerves. Histochemistry 89, 1-9 (1988
44. Elenkov, I. J., Wilder, R. L., Chrousos, G. P. & Vizi, E. S. The sympathetic nerve-An integrative interface between two supersystems: The brain and the immune system. Pharmacol. Rev. 52, 595-638 (2000
45. Nave, H. et al. Reduced tissue immigration of monocytes by neuropeptide Y during endotoxemia is associated with Y2 receptor activation. J. Neuroimmunol. 155, 1-12 (2004
46. ten Bokum, A. M., Hofland, L. J. & van Hagen, P. M. Somatostatin and somatostatin receptors in the immune system: A review. Eur. Cytokine Netw. 11, 161-176 (2000
47. Delgado, M., Pozo, D. & Ganea, D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56, 249-290 (2004
48. Kezuka, T. et al. Peritoneal exudate cells treated with calcitonin gene-related peptide suppress murine experimental autoimmune uveoretinitis via IL 10. J. Immunol. 173, 1454-1462 (2004
49. O'Connor, T. M. et al. The role of substance P in inflammatory disease. J. Cell Physiol. 201, 167-180 (2004
50. Bowler, K. E. et al. Evidence for anti-inflammatory and putative analgesic effects of a monoclonal antibody to calcitonin gene-related peptide. Neuroscience 228, 271-282 (2013
51. Peters, H. et al. Angiotensin-converting enzyme inhibition but not β-Adrenergic blockade limits transforming growth factor-β overexpression in acute normotensive anti-Thy1 glomerulonephritis. J. Hypertens. 21, 771-780 (2003
52. Ditting, T., Tiegs, G. & Veelken, R. Autonomous innervation in renal inflammatory disease-innocent bystander or active modulator?. J. Mol. Med. (Berl.) 87, 865-870 (2009
53. Symplicity HTN 1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension 57, 911-917 (2011
54. Symplicity HTN 2 Investigators et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN 2 Trial): A randomised controlled trial. Lancet 376, 1903-1909 (2010
55. Esler, M. D. et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: One-year results from the Symplicity HTN 2 randomized, controlled trial. Circulation 126, 2976-2982 (2012
56. Worthley, S. G. et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: The EnligHTN I trial. Eur. Heart J. 34, 2132-2140 (2013
57. Mahfoud, F. et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 128, 132-140 (2013
58. Persu, A. et al. Blood pressure changes after renal denervation at 10 European expert centers. J. Hum. Hypertens. 28, 150-156 (2013
59. Fadl Elmula, F. E. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 62, 526-532 (2013
60. Schmieder, R. E., Ruilope, L. M., Ott, C., Mahfoud, F. & Bohm, M. Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. J. Hum. Hypertens. 27, 715-720 (2013
61. Jackson, R., Lawes, C. M., Bennett, D. A., Milne, R. J. & Rodgers, A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 365, 434-441 (2005
62. Mancia, G. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281-1357 (2013
63. Mancia, G. & Parati, G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: A meta-Analysis. J. Hypertens. 22, 435-445 (2004
64. Ott, C. et al. Vascular and renal hemodynamic changes after renal denervation. Clin. J. Am. Soc. Nephrol. 8, 1195-1201 (2013
65. Krum, H. et al. Renal artery denervation via catheter-based delivery of low-power radiofrequency energy provides safe and durable blood pressure reduction: Complete 3 year results from SYMPLICITY HTN 1 [abstract]. Eur. Heart J. 34 (Suppl. 1), 3787 (2013
66. Esler, M. D., Krum, H., Schlaich, M., Schmieder, R. E. & Boehm, M. TCT 58 persistent and safe blood pressure lowering effects of renal artery denervation: Three year follow-up from the Symplicity HTN 2 Trial. J. Am. Coll. Cardiol. 62 (Suppl. 1), B19 (2013
67. Krum, H. et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3 year report of the Symplicity HTN 1 study. Lancet 383, 622-629 (2014
68. Kaltenbach, B. et al. Renal artery stenosis after renal sympathetic denervation. J. Am. Coll. Cardiol. 60, 2694-2695 (2012
69. Vonend, O., Antoch, G., Rump, L. C. & Blondin, D. Secondary rise in blood pressure after renal denervation. Lancet 380, 778 (2012
70. Mahfoud, F. et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60, 419-424 (2012
71. Schmieder, R. E. et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J. Am. Soc. Nephrol. 22, 1353-1364 (2011
72. Grassi, G. et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48, 1359-1365 (2005
73. Huggett, R. J. et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108, 3097-3101 (2003
74. Mahfoud, F. et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study. Circulation 123, 1940-1946 (2011
75. Witkowski, A. et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58, 559-565 (2011
76. DiBona, G. F. Sympathetic nervous system and hypertension. Hypertension 61, 556-560 (2013
77. Kurella, M., Lo, J. C. & Chertow, G. M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol. 16, 2134-2140 (2005
78. Ryu, S. et al. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am. J. Kidney Dis. 53, 59-69 (2009
79. Hering, D. et al. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23, 1250-1257 (2012
80. Kiuchi, M. G. et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur. Heart J. 34, 2114-2121 (2013
81. Schlaich, M. P. et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int. J. Cardiol. 168, 2214-2220 (2013
82. Schmieder, R. E. et al. Does renal denervation stop renal function decline in treatment resistant hypertension: Results of a pilot study [abstract]. Circulation 128, A17557 (2013
83. Mahfoud, F. et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur. Heart J. 34, 2149-2157 (2013
84. Tsioufis, C. et al. What the interventionalist should know about renal denervation in hypertensive patients: A position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention 9, 1027-1035 (2014
85. Schmieder, R. E. et al. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention 9 (Suppl. R), R58-R66 (2013
86. Schlaich, M. P. et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J. Am. Coll. Cardiol. 62, 2031-2045 (2013